If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
The below information is provided in response to your request and may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above.
Effects of teriparatide on BMD in postmenopausal women with osteoporosis
Results from a last observation carried forward (LOCF) analysis showed that FORTEO® (teriparatide [rDNA origin] injection) significantly increased baseline to endpoint bone mineral density (BMD) at the
lumbar spine (9.7%),
femoral neck (2.8%), and
total hip (2.6%) (Table 1) (Forteo Package Insert, 2012).
In a subset of women for whom data were available at every time point (3, 6, 12, and 18 months), teriparatide significantly increased lumbar spine BMD by 3.9% at 3 months of treatment and 11.8% at 18 months (Forteo Package Insert, 2012).
Effects of teriparatide on BMD in men with primary or hypogonadal osteoporosis
Using a LOCF analysis, results showed that teriparatide treatment, for a median of 10 months, significantly increased baseline lumbar spine BMD by 5.9% compared to placebo (p<.001). Significant increases in lumbar spine BMD were seen at 3 months (Forteo Package Insert, 2012).
There was no significant difference observed in the change from baseline to endpoint total hip BMD (Forteo Package Insert, 2012).
Effects of teriparatide on BMD in men and women with glucocorticoid-induced osteoporosis
Results from a LOCF analysis showed that teriparatide significantly increased baseline to endpoint BMD at the lumbar spine, femoral neck, and total hip by 7.2%, 3.6%, and 3.7%, respectively, at the 18 month endpoint (p<.001 all sites) (Forteo Package Insert, 2012).
Abbreviations: BMD = bone mineral density
a Intent-to-treat analysis, last observation carried forward
b p<.001 compared with placebo
c p<.05 compared with placebo
Enclosed Prescribing Information
The published references below are available upon request by contacting 1-800-LillyRx.
FORTEO® [Package Insert]. Indianapolis, IN: Eli Lilly and Company; 2012.
Date of Last Review: February 12, 2017